Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 5/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19692584 | 0.99 | ATF4 (0.79) | ATF4LMNAKMT2AALDH1A1HPGD | |
| SCHEMBL16082988 | 0.90 | ATF4 (1.00) | ATF4LMNAKMT2AALDH1A1HPGD | |
| SCHEMBL16082980 | 0.90 | ATF4 (1.00) | ATF4LMNAKMT2AALDH1A1HPGD | |
| SCHEMBL16083047 | 0.90 | ATF4 (1.00) | ATF4LMNAKMT2AALDH1A1HPGD | |
| SCHEMBL25538362 | 0.86 | LMNA (0.59) | ATF4LMNAKMT2AHPGDHTT | |
| SCHEMBL19134217 | 0.86 | ATF4 (0.86) | ATF4LMNAKMT2AALDH1A1HPGD | |
| SCHEMBL5123998 | 0.86 | POLB (0.62) | ATF4LMNAKMT2AALDH1A1HPGD | |
| SCHEMBL19692630 | 0.85 | ATF4 (0.59) | ATF4LMNAKMT2AALDH1A1HPGD | |
| SCHEMBL17658630 | 0.84 | ATF4 (0.89) | ATF4LMNAKMT2AALDH1A1HPGD | |
| SCHEMBL17658580 | 0.84 | ATF4 (0.89) | ATF4LMNAKMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165848-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-01 | — | — | US | disclosed |
| US-20230165848-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-01 | — | — | US | disclosed |
| US-20230165848-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-01 | — | — | US | disclosed |
| US-11547704-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-01-10 | — | — | US | disclosed |
| EP-3468960-B1 | CHEMICAL COMPOUNDS AS ATF4 PATHWAY INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-03-23 | — | — | EP | disclosed |
| CN-109563071-B | Chemical compounds as inhibitors of the ATF4pathway | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-08-03 | — | — | CN | disclosed |
| US-20200297710-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-24 | — | — | US | disclosed |
| US-20190298705-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-03 | — | — | US | disclosed |
| EP-3468960-A1 | CHEMICAL COMPOUNDS AS ATF4 PATHWAY INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-04-17 | — | — | EP | disclosed |
| CN-109563071-A | Chemical compound as ATF4 approach restrainer | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-04-02 | — | — | CN | disclosed |
| WO-2017212425-A1 | CHEMICAL COMPOUNDS AS ATF4 PATHWAY INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017212425-A1 | CHEMICAL COMPOUNDS AS ATF4 PATHWAY INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-14 | — | — | WO | disclosed |
| EP-1212299-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2009-04-08 | — | — | EP | disclosed |
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | MERRILL LYNCH CAPITAL, A DIVISION OF MERRILL LYNCH BUSINESS FINANCIAL SERVICES, INC. AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| US-6903085-B1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | ASTRAZENECA, AB (CH) | 2005-06-07 | — | — | US | disclosed |
| EP-1212299-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca UK Limited (GB) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001014333-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LIMITED (GB) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190298705-A1 | Chemical Compounds | ATF4, XBP1, EIF2B5 | ATF4 1/4885LMNA 476/4885KMT2A 3591/4885 |
| US-20200297710-A1 | Chemical Compounds | ATF4, XBP1, EIF2B5 | ATF4 1/4885LMNA 476/4885KMT2A 3591/4885 |
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | CXCR4, CXCR1, CXCR3 | ATF4 893/4885LMNA 3126/4885KMT2A 2580/4885 |
| US-20230165848-A1 | CHEMICAL COMPOUNDS | ATF4, XBP1, EIF2B5 | ATF4 1/4885LMNA 470/4885KMT2A 3707/4885 |
| US-11547704-B2 | Chemical compounds | ATF4, XBP1, EIF2B5 | ATF4 1/4885LMNA 476/4885KMT2A 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.